Objectives The evaluation of the pharmacological profile of the dried 50% hydroalcoholic extract (50%HA) of Astragali radix in two different animal models of articular damage resembling osteoarthritis and rheumatoid arthritis. Methods Sodium monoiodoacetate (MIA) or complete Freund's adjuvant (CFA) was intra-articular injected (day 0) in the rat tibiotarsal joint to induce damages mimicking osteoarthritis or rheumatoid arthritis. Pain measurements (responses to non-noxious and noxious stimuli, spontaneous pain, articular pain) were assessed on days 7 and 14. On day 14, the tibiotarsal joints were explanted in order to measure the diameter and to assess histological evaluations. Furthermore, the plasmatic concentrations of inflammatory and anti-inflammatory cytokines were measured. Key findings A single administration of 50%HA (300 mg/kg per os) significantly reduced both MIA-induced pain and CFA-induced pain (78% and 96% pain relief, respectively). The repeated administration prevented the development of hypersensitivity on day 14. The haematoxylin/eosin staining revealed that 50% HA attenuated joint alterations in MIA-injected rats, and furthermore, the joint inflammatory infiltrate was reduced in both models (by about 50%). In CFA-treated rats, 50%HA lowered the plasmatic levels of the proinflammatory cytokines interleukin-1b and tumour necrosis factor-a as well as the joint diameter. Conclusions The 50% hydroalcoholic extract of Astragali radix is a valuable candidate for the adjuvant treatment of articular diseases.
Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the major causes of joint disease among the ageing population. [1, 2] However, while OA mostly affects elderly people, disabling approximately 30% of persons age ≥65 years, RA is frequent between 30 and 50 years. [3, 4] In the articular cartilage of OA patients, the physical damage is subsequently modulated by immunological, genetic or cellular factors. The OA synovial membrane is characterized by inflammatory component even if less pronounced than in RA. [2, 5] On the other hand, RA, whose aetiology is still unknown, is a chronically inflammatory, destructive joint disease, continuously sustained by a plethora of activated cell types (dendritic cells and endothelial cells, osteoclasts, T cells and B cells, monocytes/macrophages and synovial fibroblasts) in the synovial membrane. [6] [7] [8] Furthermore, chronic pain is a hallmark of both these categories of articular diseases, with nociceptive, non-nociceptive and neuropathic features. [9] [10] [11] Pharmacological care is quite different between these arthritic diseases. While OA is mostly counteracted by pain relieving agents, RA is managed by immunesuppressive and anti-inflammatory therapy. Following the NICE Guidelines for the osteoarthritis therapy, topical non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol should be considered onwards oral opioids, cyclooxygenase 2 (COX-2) inhibitors or NSAIDs.
Otherwise, when topical NSAIDs and paracetamol are not sufficient for relieving pain of OA patients, the supplement of opioids should be taken into account. Moreover, intra-articular corticosteroid injections should be added to core treatments for the relief of moderate-to-severe pain. [12] Regarding to RA, the European League Against Rheumatism (EULAR) recommends the use of the socalled DMARDs (disease-modifying antirheumatic drugs) as soon as pathology is diagnosed. Methotrexate and/or glucocorticoids are considered the first-line agents. Leflunomide or sulfasalazine can also be used. By contrast, non-responsive patients can be treated with biological drugs in addition to conventional DMARDs, such as the TNF-a inhibitors (infliximab, certolizumab pegol, etanercept, golimumab and adalimumab), the IL-6 receptor blocking monoclonal antibody, the tocilizumab, as well as the IL-1 inhibitor, anakinra. [13] However, since the chronicity of therapy and adverse effects associated with the majority of these drugs, the management of arthritic diseases remains clinically challenging. In this context, plant extracts with a favourable safety profile emerge as interesting therapeutic resources for the treatment of chronic pathologies.
In this context, Astragali radix from Astragalus membranaceus (Fisc.) Bunge (Fabaceae) is one of the mostly used medicinal herbs of the traditional Chinese medicine having numerous medicinal properties and significant safety profile. The herbal drug is recently introduced in the European Pharmacopoeia. [14, 15] Astragali radix extracts have been reported to have several biological functions among which immunomodulatory and hepatoprotective ones. [16, 17] Furthermore, antiviral and antioxidant activity have been highlighted. [18, 19] To note, the major active compounds of Astragalus are flavonoids, saponins and polysaccharides, reported to have anti-inflammatory effects [20, 21] and anti-arthritic activity. [22] [23] [24] Recently, we have chemically characterized and tested the antineuropathic effects of different aqueous and hydroethanolic extracts from Astragali radix. The most active extract of both in vitro and in vivo experiments resulted a 50% hydroalcoholic extract (50%HA). [25, 26] The aim of this study was to assess, for the first time, the pharmacological profile of the Astragali radix phytocomplex, as present in 50%HA, in two rat models of articular diseases resembling OA and RA, respectively. 50% HA (300 mg/kg) was acutely and chronically administered in monoiodoacetate (MIA)-treated rats or complete Freund's adjuvant (CFA)-treated rats and pain behavioural measurements were assessed. Moreover, exvivo analyses were performed to evaluate joint alterations and plasma levels of characteristic cytokines. The possible application of the rapid clinically translatable botanical 50%HA was enquired.
Materials and Methods

Plant material, and analysis
The 50 % hydroalcoholic dried extract of Astragali radix (Axtragyl TM ) was purchased from Giellepi S. p. A. Health Science Division. The extract was reported to contain 30 % maltodextrins as excipients. For the quantitative HPLC analysis, the following standards were used: astragaloside IV, European Pharmacopoeia (EP) reference standard (97.8 %) and formononetin (≥99 % by HPLC) from (Sigma-Aldrich, Milano, Italy). Dextrans with increasing and defined molecular weights (5000, 150 000, 270 000, 670 000 Da) were from Sigma-Aldrich. The full characterization of the Astragalus extract was previously published [25] and described in the supplementary material (Appendix S1). An authentic sample of the commercial dried extract is deposited at the Department of Chemistry, University of Florence.
Animals
Male Sprague-Dawley (SD) rats (Envigo, Varese, Italy) weighing approximately 200-250 g at the beginning of the experimental procedure were used. Animals were housed in CeSAL (Centro Stabulazione Animali da Laboratorio, University of Florence) and used at least 1 week after their arrival. Four rats were housed per cage (size 26 9 41 cm) kept at 23 AE 1°C with a 12-h light/dark cycle, light at 7 a.m., and were fed a standard laboratory diet and tap water ad libitum. All animal manipulations were carried out according to the Directive 2010/63/EU of the European Parliament and of the European Union Council (22 September 2010) on the protection of animals used for scientific purposes. The ethical policy of the University of Florence complies with the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85-23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct the experiments described was obtained from the Animal Subjects Review Board of the University of Florence. Experiments involving animals have been reported according to the ARRIVE guidelines. [27] All efforts were made to minimize animal suffering and to reduce the number of animals used.
Monoiodoacetate-induced osteoarthritis
Unilateral osteoarthritis was induced by injection of monoiodoacetate (MIA; Sigma-Aldrich, Milan, Italy) into the tibiotarsal joint. [10] On day 0, rats were slightly anaesthetized by 2% isoflurane, the left leg skin was sterilized with 75% ethyl alcohol and the lateral malleolus located by palpation; then, a 28-gauge needle was inserted vertically to penetrate the skin and turned distally for insertion into the articular cavity at the gap between the tibiofibular and tarsal bone until a distinct loss of resistance was felt. Two milligrams of MIA in 25 ll saline was delivered into the left articular cavity. Control rats were treated with an equal volume of saline.
Complete Freund's adjuvant-induced inflammatory arthritis Articular damage was induced by injection of complete Freund's adjuvant (CFA; Sigma-Aldrich, Milan, Italy) into the tibiotarsal joint. [10, 28] Briefly, the rats were lightly anaesthetized by 2% isoflurane, the left leg skin was sterilized with 75% ethyl alcohol and the lateral malleolus located by palpation; then, a 28-gauge needle was inserted vertically to penetrate the skin and turned distally for insertion into the articular cavity at the gap between the tibiofibular and tarsal bone until a distinct loss of resistance was felt. A volume of 50 ll of CFA was then injected (day 0). Control rats received 50 ll of saline solution (day 0) in the tibiotarsal joint.
Drug treatment
For the acute treatment, 50% HA was suspended in 1% carboxymethylcellulose (CMC) and once administered p.o. at the dose of 300 mg/kg on day 7 or on day 14 after MIA or CFA injection. For the chronic treatment, 50% HA (300 mg/kg p.o.) was administered every day for 2 weeks starting from the 1st day of MIA or CFA injection.
Paw pressure test
The nociceptive threshold in the rat was determined with an analgesimeter (Ugo Basile, Varese, Italy), according to the method described by Leighton et al. [29] Briefly, a constantly increasing pressure was applied to a small area of the dorsal surface of the hind paw using a blunt conical mechanical probe. Mechanical pressure was increased until vocalization or a withdrawal reflex occurred while rats were lightly restrained. Vocalization or withdrawal reflex thresholds were expressed in grams. Rats scoring below 40 g or over 75 g during the test before drug administration (25%) were rejected. An arbitrary cut-off value of 100 g was adopted. The data were collected by an observer who was blinded to the protocol.
Incapacitance test
Weight bearing changes were measured using an incapacitance apparatus (Linton Instrumentation, Palgrave, UK) detecting changes in postural equilibrium after a hindlimb injury. [30] Rats were trained to stand on their hind paws in a box with an inclined plane (65°from horizontal). This box was placed above the incapacitance apparatus. This allowed us to independently measure the weight that the animal applied on each hindlimb. The value considered for each animal was the mean of five consecutive measurements. In the absence of hindlimb injury, rats applied an equal weight on both hindlimbs, indicating a postural equilibrium, whereas an unequal distribution of the weight on hindlimbs indicated a monolateral decreased pain threshold. Data are expressed as the difference between the weight applied on the limb contralateral to the injury and the weight applied on the ipsilateral one (D Weight).
von Frey test
The animals were placed in 20 9 20 cm plexiglas boxes equipped with a metallic meshy floor, 20 cm above the bench. A habituation of 15 min was allowed before the test. An electronic von Frey hair unit (Ugo Basile) was used: the withdrawal threshold was evaluated by applying force ranging from 0 to 50 g with a 0.2-g accuracy. Punctuate stimulus was delivered to the mid-plantar area of each anterior paw from below the meshy floor through a plastic tip, and the withdrawal threshold was automatically displayed on the screen. Paw sensitivity threshold was defined as the minimum pressure required to elicit a robust and immediate withdrawal reflex of the paw. Voluntary movements associated with locomotion were not taken as a withdrawal response. Stimuli were applied on each anterior paw with an interval of 5 s. The measure was repeated 5 times, and the final value was obtained by averaging the five measures. [31] Pressure application measurement test
The pressure application measurement (PAM from Ugo Basile) was used to measure mechanical pain threshold of the knee joint. A force transducer (2 mm diameter) is mounted on the operator's thumb, and a progressive quantified force was applied for direct stimulation of the joint. The rate of application of the force is decided by the operator. The force (gram-force; gf) which elicits the animal response (normally, limb withdrawal) was recorded. The value considered for each joint was the mean of five consecutive measurements. Data are expressed as the difference between the force tolerated on the knee joint contralateral to the injury and the force tolerated on the ipsilateral one (D Force).
Histological evaluations
Animals were killed by cervical dislocation. Legs were cut under the knee, flayed and fixed in 4% formaldehyde in phosphate-buffered saline (PBS) for 48 h at room temperature. Subsequently, samples were decalcified by 0.76 M sodium formate and 1.6 M formic acid solution in H 2 O for 4 weeks with a change of solution every 7 days. At the end of the decalcification, these samples were routinely dehydrated in alcohol and embedded in paraffin. Sections 6 lM thick of tibiotarsal joint and of phlogistic-fibrous pannus located around the join were obtained. Sections were haematoxylin-eosin stained. In the phlogistic-fibrous pannus sections, the number of inflammatory cells was counted, and results were expressed as number of inflammatory cells/microscopic field. Sections of the joint were analysed qualitatively by two independent observers in a blind fashion.
Cytokine plasma levels
Plasmatic IL-1b, TNF-a, TGF-b1, IL-10 levels were evaluated by ELISA method (eBioscience, San Diego, CA, USA), using a specific anti-rat polyclonal antibody. To obtain detectable levels of cytokines, plasma samples were lyophilized and reconstituted in 1/5 of the initial volume. Range sensitivity was 8-1000 pg/ml.
Joint diameter evaluation
Animals were killed, and legs ipsilateral to CFA injection were cut and fixed as described before in 'Histological evaluations' section. Then, the diameter of the tibiotarsal joint was measured using a digital caliper (150 mm).
Statistical analysis
Each value represents the mean AE SEM of five rats per group, performed in two different experimental sets. Groups were as shown in the figures, and different groups were used for acute and repeated treatments. The analysis of variance was performed by ANOVA. A Bonferroni's significant difference procedure was used as post hoc comparison. P values of less than 0.05, 0.01 or 0.001 were considered significant. Data were analysed using the 'Origin 8.1' software.
Results
Extract characterization
According to a previous characterization, [25] the drug extract ratio (DER) of 50 %HA was 1/4-6. Characteristic constituents, namely saponins (expressed as astragaloside IV) and isoflavones (expressed as formononetin), were analysed by LC/DAD/MS. The developed analytical methods were similar to those reported in the literature for the simultaneous determination of isoflavones and saponins, modified according to our specific needs. To achieve optimized separation, the same gradient reported in the literature was used, with slight modifications. Astragaloside IV and formononetin international standards were used to quantify saponins and isoflavones, respectively. Calibration curves of both constituents were prepared between 0.01 and 10 lg/ml, and each calibration level was analysed six times by LC-DAD (isoflavones) or LC-MS (saponins) methods. A good linear relationship over the tested ranges was found. The LOQ of formononetin was 0.5 lg/ml and the LOQ of astragaloside IV was 0.01 lg/ml. According to the literature data, very low amounts of both classes of constituents were found, as reported in Table S1 .
According to the HPLC analysis, polysaccharides represent the major constituents of the extracts. Accordingly, the extracts were firstly analysed by NMR to elucidate the monomers present in the polysaccharide sequence and then by dynamic light scattering (DLS) to give an averaged molecular weight. The 1 H NMR spectra of the Astragalus extract displayed two clear peaks in the anomeric region (between 4.0 and 5.4 ppm), and all three extracts were very similar ( Figure S1 ). The peaks between 4.00 and 5.30 ppm were clearly identified as the anomeric protons. The other carbinolic peaks overlap but can be easily observed in the HMQC experiments ( Figure S2 ) and assigned to hexose moieties.
The molecular weight of the polysaccharides was evaluated by DLS, namely a calibration curve was created using commercial dextrans with increasing and defined molecular weights (M w : 5000, 150 000, 270 000, 670 000). Concentrations of the extract in the tested solutions (0.5-1 mg/ml dried extract) were optimized to have a good calibration curve with an acceptable PDI and count rate. The sample showed two populations of polysaccharides, the main one ranging from 75 % to 97 %, and the molecular weights of populations were calculated by the value of Z average using the calibration curve of standard dextrans (Table S2) .
Behavioural measurements
Behavioural tests were assessed to evaluate the pain reliever effect of single and repeated administrations of 50%HA on MIA-treated rats or CFA-treated rats.
As shown by Paw pressure test, on day 14 from injection, MIA significantly lowered the pain threshold on the ipsilateral paw in response to a mechanical noxious stimulus (pretest, Figure 1a ) as well as increased the hindlimb bearing between the contralateral and the ipsilateral paw, as assessed by the incapacitance test (pretest, Figure 1b) . A single injection of 50%HA (300 mg/kg p.o.) on MIA plus vehicle group was able to significantly reduce both the withdrawal threshold in response to a noxious mechanical stimulus and postural unbalance, peaking 45 min after injection (Figure 1) . However, the effect of MIA on pain perception was visible also on day 7. As shown in Figure S3 , MIA injection reduced both the weight tolerated on the ipsilateral paw and increased the postural unbalance (pretest, Figure S3a and S3b). 50%HA (300 mg/kg), acutely injected p.o. on MIA plus vehicle-treated animals, was able to significantly increase the withdrawal threshold in response to a noxious mechanical stimulus and to lower the D weight between the contralateral and the ipsilateral paw, exerting the maximum effect 30 min after injection ( Figure S3a and S3b). The pain reliever effect of 50%HA has been highlighted even after daily administration. As depicted in Figure 2a , on day 14, 50%HA repeatedly administered (300 mg/kg p.o.), significantly increased the weight tolerated on the ipsilateral paw (47.5 AE 1.7 g, MIA plus vehicle vs 65.0 AE 3.5 g, MIA plus 50%HA) (Figure 2a) . Furthermore, chronic 50%HA significantly reduced spontaneous pain (48.1 AE 9.2 g, MIA plus vehicle vs 25.0 AE 5.0 g, MIA plus 50%HA) (Figure 2b ). As measured by von Frey apparatus, MIA, 14 days after injection, lowered the pain threshold in response to a non-noxious mechanical stimulus, meanwhile 50%HA, daily administered, was not able to significantly prevent the pain sensitivity increase (Figure 2c) . Finally, as depicted in Figure 2d , the PAM test allowed to evaluate the articular pain as the difference (D Force) between the force tolerated on the joint contralateral to the injury and the force tolerated on the ipsilateral one. On day 14, D force was increased in MIA plus vehicle rats with respect to vehicle plus vehicle group (284.0 AE 38.9 gf, MIA plus vehicle vs 61.7 AE 17.3 gf, vehicle plus vehicle). 50%HA, daily injected, completely reverted articular pain (41.5 AE 14.6 gf) ( Figure 2d) .
As shown in Figure 3 , CFA significantly decreased the withdrawal threshold in response to a noxious mechanical stimulus 14 days after injection (pretest, Figure 3a) . Moreover, postural unbalance was increased after CFA injection (pretest, Figure 3b ). Paw pressure test led us to appreciate that a single administration of 50%HA (300 mg/kg p.o.) was able to significantly increase the weight tolerated on the ipsilateral paw up to 45 min after injection (Figure 3a) . Furthermore, the herbal extract reduced CFA-induced spontaneous pain from 15 to 45 min, as shown by the incapacitance test (Figure 3b ). As depicted in Figure 4a , CFA significantly decreased the withdrawal threshold in response to a noxious mechanical stimulus as well as reduced spontaneous pain also on day 7 after injection ( Figure 4a and 4b) . However, 50% HA (300 mg/kg), daily administered per os, was able to exert pain reliever activity on day 14, where it increased the weight tolerated on the ipsilateral paw (38.0 AE 3.3 g, CFA plus vehicle vs 54.7 AE 2.4 g, CFA plus 50%HA) (Figure 4a) . Moreover, as assessed by the incapacitance test, chronic treatment of 50%HA significantly reduced the postural unbalance (60.8 AE 6.3 g, CFA plus vehicle vs 28.4 AE 5.4 g, CFA plus 50%HA) (Figure 4b ). The von Frey apparatus showed that 50%HA, daily administered, reduced the withdrawal threshold lowering in response to Figure 1 Monoiodoacetate-induced arthritis. 50%HA acute treatment, behavioural measurements. 50%HA (300 mg/kg) was administered p.o. on day 14 after monoiodoacetate injection. Behavioural tests were performed 15, 30, 45, 60 and 75 min after astragalus administration. (a) The response to a noxious mechanical stimulus was measured by the Paw pressure test. (b) Spontaneous pain was assessed measuring the hindlimb weight bearing alterations using the incapacitance test; data are expressed as the difference between the weight applied on the limb contralateral to the injury and the weight applied on the ipsilateral limb. Each value represents the mean AE SEM of five rats per group, performed in two different experimental sets. ***P < 0.001 vs vehicle plus vehicle (pretest).^P < 0.05,^^P < 0.01 and^^^P < 0.001 vs monoiodoacetate plus vehicle (pretest).
a mechanical non-noxious stimulus induced by CFA (20.1 AE 1.7 g, CFA plus vehicle vs 10.4 AE 0.9 g, CFA plus 50%HA) (Figure 4c) . Furthermore, as depicted in Figure 4d , articular pain dramatically increased after the CFA injection (À6.4 AE 5.6 gf, vehicle plus vehicle vs 176 AE 13.9 gf, CFA plus vehicle), meanwhile 50%HA lowered the D force impairment tolerated on the contralateral and ipsilateral joint (89.7 AE 10.8 gf) (Figure 4d) .
Seven days of treatment with 50%HA was not enough to induce pain relief (24 h after administration) in both models (Figures 2a and 2b , and 4a and 4b).
Morphological evaluation of tibiotarsal joint
The effect of repeated administration of 50%HA on morphological derangement of tibiotarsal joint was evaluated 14 days after MIA or CFA injection.
In MIA osteoarthritis model, the intra-articular injection of MIA caused fibrin accumulation and broad degeneration of the articular cartilage characterized by thickness reduction, ulceration and scarring. As result, the intra-articular space markedly decreased with respect to the normal joint. 50%HA (300 mg/kg) daily administration weakly reduced the fibrin accumulation ( Figure 5, panel a) . Moreover, the treatment Figure 2 Monoiodoacetate-induced arthritis. 50%HA repeated treatment, behavioural measurements. After monoiodoacetate injection (day 0), 50%HA (300 mg/kg) was daily administered p.o. for 14 days. The Paw pressure test and the incapacitance test were performed on days 7 and 14, 24 h after the last treatment; the von Frey test and the PAM test were performed on day 14, 24 h after the last treatment. (a) The response to a noxious mechanical stimulus was measured by the Paw pressure test. (b) Spontaneous pain was assessed measuring the hindlimb weight bearing alterations by the incapacitance test; data are expressed as the difference between the weight applied on the contralateral and ipsilateral limbs. (c) The response to a non-noxious mechanical stimulus was measured by the von Frey test. (d) Articular pain was assessed by the PAM test; data are expressed as the difference between the forces tolerated on the contralateral and the ipsilateral joints. Each value represents the mean AE SEM of five rats per group, performed in two different experimental sets. *P < 0.05, **P < 0.01 and ***P < 0.001 vs vehicle plus vehicle. P < 0.05 and^^P < 0.01 vs MIA plus vehicle.
with Astragalus extract significantly lowered the number of inflammatory cells in the phlogistic-fibrous tissue located around the joint, as shown in Figure 5 (panels b and c).
As shown in Figure 6 , CFA injection induced the total ablation of the joint space that appears replaced by fibrous tissue. Articular cartilage was completely disappeared (CFA plus vehicle vs vehicle plus vehicle) ( Figure 6, panel a) . Animals treated with the herbal extract showed morphological features very similar to those expressed by animal treated with CFA: ablation of the joint space, which is occupied by fibrous tissue. The treatment with 50%HA significantly reduced the number of inflammatory cells in the phlogistic-fibrous tissue located around the joint, as shown in Figure 6 (panels b and c) . Moreover, CFA injection increased the joint diameter with respect to the vehicle plus vehicle group, as measured with caliber (9.16 AE 0.44 mm, CFA plus vehicle vs 6.03 AE 0.03 mm, vehicle plus vehicle) (Figure S4a) . On the other hand, chronic administration of 50%HA significantly reduced articular swelling (7.83 AE 0.16 mm) ( Figure S4a ).
Cytokine levels evaluation
On day 14 days after the CFA injection, the biochemical analysis of plasma fluids was performed. The evaluation revealed a twofold increase in Il-1b levels in CFA-treated animals with respect to vehicle plus vehicle group. As shown in Table 1 , 50%HA chronic treatment was able to completely prevent the Il-1b level increase (Table 1) .
Moreover, the herbal extract significantly reduced the TNFa plasma concentration increase caused by CFA (18.0 AE 2.8 pg/ml, CFA plus 50%HA vs 35.0 AE 3.4 pg/ml, CFA plus vehicle). On the other hand, 50%HA did not affect the plasma levels of TGF-b and IL-10. Notably, CFA did not influence the concentration of TGF-b1 14 days after injection (77.8 AE 1.5 pg/ml, CFA plus vehicle vs 85.4 AE 2.8 pg/ml, vehicle plus vehicle).
Discussion
The present data highlight the anti-arthritic effect of a 50% hydroalcoholic extract obtained from Astragali radix (50% HA) in two rat models of articular painful damages.
In the first paradigm, the intra-articular injection of MIA provided a monolateral osteoarthritis with features, such as cartilage fibrillation, formation of osteophytes, thickening and loss of cartilage, similar to those seen in humans. [32] [33] [34] Structural changes of the articular morphology are related to the onset of a long-lasting inflammatory pain which acquires neuropathic hallmarks starting from the 14th day after MIA injection. [10, 35] The present results showed that 50%HA (300 mg/kg) is highly active after a single oral administration reducing the response to a suprathreshold stimulation (hyperalgesia-related stimulation) and the postural unbalance (spontaneous pain) both 7 and 14 days after MIA injection. These data led us to appreciate that the 50%HA is able to relieve pain sensitivity during both the inflammatory and the, subsequent, neuropathic phase of osteoarticular Spontaneous pain was assessed measuring the hindlimb weight bearing alterations using the incapacitance test; data are expressed as the difference between the weight applied on the limb contralateral to the injury and the weight applied on the ipsilateral limb. Each value represents the mean AE SEM of five rats per group, performed in two different experimental sets. **P < 0.01 and ***P < 0.001 vs vehicle plus vehicle (pretest).^P < 0.05,^^P < 0.01 vs complete Freund's adjuvant plus vehicle (pretest).
pain. Moreover, the repeated treatment with 50%HA for 14 days reduces spontaneous pain and completely reverts both pain evoked by noxious stimulus applied on the paw as well as pain directly measured on the joint. As such, the effect of chronic 50%HA on pain relief is accompanied with the morphological recovery of the joint. The histological evaluation confirms that the daily administration of Astragalus extract reduces inflammatory infiltrate and fibrin accumulation around the joint. Thus, the capability of 50%HA to decrease the painful sensitivity could be due to a dual action: by a mechanism that quickly lowers pain and inflammation and favouring articular restoration.
50%HA relieves pain even in rats where arthritis was induced by the adjuvant injection. CFA, once injected into the tibiotarsal joint, causes an inflammatory arthritis resembling to rheumatoid arthritis. [36] Inflammation induced by CFA begins on the 3rd day after injection and holds steady up to day 14, increasing pain sensitivity. [37, 38] Interestingly, Astragalus extract was able to completely revert pain, after a single injection on day 14, when the disease was already full-blown. Moreover, 50%HA efficacy was maintained also after repeated treatments reducing the pain towards noxious and non-noxious mechanical stimuli as well as spontaneous and articular pain. Histologically, CFA injection led to an intense inflammatory state and swelling severely altering the joint morphology. [39] Although chronic 50%HA does not enhance the morphological recovery of the joint, the articular inflammation is reduced as well as the joint diameter. The slowing of disease progression, as evidenced by histological data, was confirmed analysing the levels of pro-inflammatory cytokines TNF-a and Il-1b that are strongly involved in the pathogenesis of RA. [40, 41] 50%HA significantly lowered the plasmatic levels of both TNF-a and Il-1b. Conversely, 50%HA did not influence the concentrations of the anti-inflammatory TGF-b1 and IL-10, both related to RA-induced inflammation. [42, 43] Several bioactive compounds were found in Astragali radix, namely triterpene saponins mainly astragaloside IV, [44] flavonoids, mainly calycosin and formononetin [45] and polysaccharides. [46] Chemical analysis of the investigated 50% HA (DER, 1/4-6 [25] ) revealed that it is mainly constituted of polysaccharides. Isoflavones represent 0.13% and were identified as calycosin, both in the free and in the glycosylated form, and formononetin. Saponins content is threefold higher than flavonoids (0.47%). [25] Previously published data on these compounds sustain the present evidence of Astragalus efficacy in articular diseases. Huh and colleagues (2010) highlighted a controversial activity of formononetin on human subchondral osteoblasts obtained from healthy and osteoarthritic patients. Although formononetin increased the osteolytic activity in normal conditions, it interfered with the osteoblast metabolism limiting the subchondral remodelling during disease. [23] Calycosin, intra-articular injected in an animal model of OA, decreased the synovial fluid production as well as reduced the subchondral bone damage. Intriguingly, the anti-inflammatory activity exerted by calycosin is not mediated by a cyclooxygenase (COX) inhibition mechanism. [22] Moreover, astragaloside IV inhibited macrophage activation during RA preventing the inflammatory-mediated cartilage and bone erosion, [24] and the immunomodulatory activity of Astragalus saponins is well known. [47, 48] Finally, polysaccharides isolated from Astragali radix lowered plasma levels of TNF-a and Il-1b and reduced the inflammation of knee synovial tissue in a rat model of RA. [49] Furthermore, articular disease is characterized by oxidative stress, occurring both acutely, with augmented local ROS production, and chronically, consequently to the inflammatory response and tissue After CFA injection (day 0), 50%HA (300 mg/kg) was daily administered p.o. for 14 days. On day 14, plasma samples were collected and analysed by ELISA kit. Protein concentrations are expressed in pg/ml. Each value represents the mean AE SEM of five rats performed in two different experimental sets. *P < 0.01 compared to vehicle plus vehicle rats; **P < 0.05 vs CFA plus vehicle.
degeneration at the joint level. Notably, oxidative levels increase contributes to pain sensitization in arthritis. [10] Interestingly, polysaccharides, flavonoids and saponins possess considerable activity against oxidative imbalance, [46, 50, 51] and 50%HA has shown antioxidant and pain relieving activity in a rat model of neuropathic pain. [26] In this context, the antioxidant properties of bioactive compounds present in 50%HA could explain at least in part the pain relieving efficacy and the anti-inflammatory activity of the herbal extract.
Taken together, the present results show the ability of 50%HA to block articular pain after acute and repeated treatments. Pain relief and joint restoration induced by 50%HA may be related to the presence of chemical components able to reduce the inflammatory state and limit the bone remodelling of the joint, although differently between the two kinds of arthritis. The marked decrease in proinflammatory cytokines, such as TNF-a and Il-1b, obtained after repeated administration of 50%HA is a significant hallmark of chronic inflammation decrease. [38] To note, formononetin and astragalosides have been proven as antinociceptive compounds in inflammatory pain. [52, 53] 50%HA is a candidate to be a widespread pain killer active against different kinds of persistent pain as neuropathic [26] and arthritic conditions [present data]. Efficacy is supported by a good safety profile highlighted by monitoring neurological, hepatic and renal alterations. [26] 
Conclusions
This study provides evidences of the pain reliever efficacy of the Astragali radix 50% hydroalcoholic extract. Preclinical conditions mimicking both osteoarthritis and rheumatoid arthritis are sensitive to 50%HA after acute and repeated oral treatments. The possibility to directly modify joint inflammation and derangement candidates 50% HA as adjuvant for the prevention and the treatment of arthritis induced by different pathogenesis. Safety characteristics and the possible use as dietary supplement make 50%HA suitable for a clinical validation.
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